Celgene Corp (CELG)

116.56
1.10 0.91
NASDAQ : Health Care
Prev Close 117.63
Open 118.20
Day Low/High 115.92 / 118.30
52 Wk Low/High 92.98 / 137.54
Volume 5.08M
Avg Volume 4.59M
Exchange NASDAQ
Shares Outstanding 775.20M
Market Cap 92.15B
EPS 2.00
P/E Ratio 45.20
Div & Yield N.A. (N.A)

Latest News

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.

Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...

Celgene Corporation, Dana-Farber Cancer Institute And University Of Arkansas For Medical Sciences Establish The Myeloma Genome Project

Celgene Corporation, Dana-Farber Cancer Institute And University Of Arkansas For Medical Sciences Establish The Myeloma Genome Project

Celgene Corporation (NASDAQ:CELG), Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences today announced the creation of the Myeloma Genome Project, a collaborative initiative aimed at compiling...

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.

'Mad Money' Lightning Round: Gilead Sciences, Celgene, Express Scripts

'Mad Money' Lightning Round: Gilead Sciences, Celgene, Express Scripts

Jim Cramer says he prefers Celgene to Gilead, and Walgreens Boots Alliance to Express Scripts.

Jim Cramer's 'Mad Money' Recap: Investors See Washington Going Pro-Business

Jim Cramer's 'Mad Money' Recap: Investors See Washington Going Pro-Business

Jim Cramer remains a fan of industrials, transports, banks and domestic oil producers.

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.

Crude Surge Marches Dow to Near Record Close

Crude Surge Marches Dow to Near Record Close

Wall Street was torn in two with the energy sector marching the Dow Jones Industrial Average higher, while health care and tech weighed on the Nasdaq.

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

The Dow Jones Industrial Average leads markets on Wednesday as a rally in crude oil lights a fire under the energy sector.

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Starbucks, Facebook, Apple: Doug Kass' Views

Starbucks, Facebook, Apple: Doug Kass' Views

Doug Kass shares his thoughts on how faster growth won't be easy and how the debt and deficits are out of control.

C, AAPL, FB: Jim Cramer's Views

C, AAPL, FB: Jim Cramer's Views

Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.

Nearly 350 Abstracts Evaluating Celgene Therapies To Be Presented At American Society Of Hematology Annual Meeting (ASH)

Nearly 350 Abstracts Evaluating Celgene Therapies To Be Presented At American Society Of Hematology Annual Meeting (ASH)

Celgene Corporation (NASDAQ:CELG) today announced that data from nearly 350 abstracts, including more than 150 oral presentations, evaluating Celgene investigational agents and investigational uses of marketed products will...

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

Celgene Corporation To Webcast An Analyst And Investor Event From The American Society Of Hematology Meeting In December

Celgene Corporation To Webcast An Analyst And Investor Event From The American Society Of Hematology Meeting In December

Celgene Corporation (NASDAQ:CELG) plans to webcast an analyst and investor event being held at the American Society of Hematology (ASH) meeting in San Diego on December 4.

Allergan, Apple and Cisco: Doug Kass' Views

Allergan, Apple and Cisco: Doug Kass' Views

Doug Kass shares his thoughts on considering the contrary and shorting the Cisco Kid.

WFC, CELG, MU: Jim Cramer's Views

WFC, CELG, MU: Jim Cramer's Views

Cramer shares his views on why some still want to buy Bank of America. Wells Fargo, Celgene and Micron are among the stocks discussed.

Facebook, Home Depot, Disney: Doug Kass' Views

Facebook, Home Depot, Disney: Doug Kass' Views

Doug Kass shares his thoughts on contrariness and his takeaways and observations on the market.

Cramer: Why Are These Stocks Doing Well?

Cramer: Why Are These Stocks Doing Well?

Suspicious minds want to know.

Celgene Rally Is No Flash in the Pan; More Gains to Come

Celgene Rally Is No Flash in the Pan; More Gains to Come

It looks like CELG could retest the highs around $140.

Data On Early Onset Of Efficacy For Oral OTEZLA® (apremilast) In Active Psoriatic Arthritis Presented At American College Of Rheumatology

Data On Early Onset Of Efficacy For Oral OTEZLA® (apremilast) In Active Psoriatic Arthritis Presented At American College Of Rheumatology

Celgene Corporation (NASDAQ: CELG) today announced findings from the ACTIVE phase 3b clinical trial of OTEZLA ® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), at the 2016 American...

Allergan, Macy's, Apple: Doug Kass' Views

Allergan, Macy's, Apple: Doug Kass' Views

Doug Kass shares his thoughts on closed-end municipal bond funds.

SBUX, K, PEP: Jim Cramer's Views

SBUX, K, PEP: Jim Cramer's Views

Cramer shares his views on looking at oil now that the election is over. Starbucks, Kellogg and PepsiCo are among the stocks discussed.

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

Bearish? Who, Me?

I should be, but I'm not. Here's why.

Jim Cramer's Top Takeaways: Chipotle, Merck, Pfizer

Jim Cramer's Top Takeaways: Chipotle, Merck, Pfizer

Cramer sees progress at Chipotle and takes a closer look at health care stocks.